Inotuzumab ozogamicin as chemotherapy-sparing salvage in a 67-year-old man with primary refractory B-cell acute lymphoblastic leukemia with high-risk genomic features
Older adults with acute lymphoblastic leukemia (ALL) continue to have a poor prognosis, in part due to greater chemotherapy-related toxicities. We herein report a 67-year-old man with Philadelphia chromosome (Ph)-negative B-cell ALL, who exhibited refractoriness to 3 different regimens of induction...
Main Authors: | Xiaochuan Yang, Filiz Sen, Mark B. Geyer |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-01-01
|
Series: | Leukemia Research Reports |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2213048919300494 |
Similar Items
-
Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia
by: Luca Bertamini, et al.
Published: (2018-11-01) -
Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia
by: Uy N, et al.
Published: (2018-04-01) -
Profile of inotuzumab ozogamicin and its potential in the treatment of acute lymphoblastic leukemia
by: Thomas X
Published: (2014-04-01) -
Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma
by: Amandeep Aujla, et al.
Published: (2019-04-01) -
Burden of hospitalization in acute lymphoblastic leukemia patients treated with Inotuzumab Ozogamicin versus standard chemotherapy treatment
by: David I. Marks, et al.
Published: (2019-10-01)